Cargando…

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma

Although melanoma is one of the most immunogenic tumors, it has an ability to evade anti-tumor immune responses by exploiting tolerance mechanisms, including negative immune checkpoint molecules. The most extensively studied checkpoints represent cytotoxic T lymphocyte-associated protein-4 (CTLA-4)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrova, Vera, Arkhypov, Ihor, Weber, Rebekka, Groth, Christopher, Altevogt, Peter, Utikal, Jochen, Umansky, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178114/ https://www.ncbi.nlm.nih.gov/pubmed/32235439 http://dx.doi.org/10.3390/ijms21072367

Ejemplares similares

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
por: Arkhypov, Ihor, et al.
Publicado: (2020)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
por: Arkhypov, Ihor, et al.
Publicado: (2022)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression
por: Groth, Christopher, et al.
Publicado: (2021)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
por: Weber, Rebekka, et al.
Publicado: (2020)

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
por: Fleming, Viktor, et al.
Publicado: (2018)

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
por: Hüser, Laura, et al.
Publicado: (2020)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
por: Bitsch, Rebekka, et al.
Publicado: (2022)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies
por: Hüser, Laura, et al.
Publicado: (2019)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Secretogranin II influences the assembly and function of MHC class I in melanoma
por: Steinfass, Tamara, et al.
Publicado: (2023)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6
por: Vierthaler, Marlene, et al.
Publicado: (2022)

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
por: Federico, Aniello, et al.
Publicado: (2020)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells
por: Granados, Karol, et al.
Publicado: (2020)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
por: Tolle, Fabrice, et al.
Publicado: (2021)

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

Melanoma Cellular Plasticity
por: Novak, Daniel, et al.
Publicado: (2022)

ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12
por: Kloss, Loreen, et al.
Publicado: (2019)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
por: Simon, Sonja C. S., et al.
Publicado: (2023)

Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage
por: Fehrenbach, Sabrina, et al.
Publicado: (2016)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
por: Wagner, Nikolaus B., et al.
Publicado: (2019)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Tackling malignant melanoma epigenetically: histone lysine methylation
por: Orouji, Elias, et al.
Publicado: (2018)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment
por: Larribère, Lionel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_envhlq2a87142nri83b51tv7e2